I'm a finance professional with a background in M&A and strategy consulting, currently pursuing my MS in Finance at Johns Hopkins University with a focus on healthcare. I find the economics of drug development genuinely fascinating. The interplay between clinical probability, capital structure, and regulatory risk is unlike anything else in finance.
This site is where I think out loud. The tools are things I built because I wanted them to exist: open, free, and grounded in how biotech finance actually works. The blog posts are analyses I would've wanted to read when I started going deep on this space.
Experience
Forstmann & Co.
Investment Banking · M&A Advisory
Built complex financial models, conducted due diligence, and prepared investment committee materials for institutional clients in aerospace M&A.
Infinite Prospects
Entertainment Finance · Conglomerate Strategy
Led financial analysis for entertainment industry expansion strategy. Developed valuation models and scenario analyses for conglomerate diversification initiatives.
Ernst & Young (EY)
Consulting
Strategy and transaction advisory. Developed frameworks for operational improvement and financial optimization across multiple industries.
Education
Johns Hopkins University — Carey Business School
MS Finance Candidate · Healthcare Focus
Coursework in drug development economics, health informatics, FDA/EMA regulatory frameworks, and healthcare equity valuation. BIWS certified.
Purdue University Global
BS · Magna Cum Laude
Areas I Work In
Beyond the Spreadsheet
Mountaineering enthusiast. The discipline required at altitude translates directly to navigating high-stakes financial decisions.
Passionate about ocean conservation. Because building sustainable companies should extend to the planet, not just the balance sheet.
Working on something interesting?
Questions about biotech finance, valuation methodology, or the tools? Say hello.